Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
Go back to Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease| (NASDAQ: OCUL) | Delayed: 10.48 +0.51 (5.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.97 | 52 Week High | $14.50 | |||
| Open | $9.83 | 52 Week Low | $4.04 | |||
| Day High | $10.59 | P/E | N/A | |||
| Day Low | $9.80 | EPS | $0.00 | |||
| Volume | 1,228,569 | |||||
